Email *

Message *

CANSWERIST® via @flipboard

Today's Tweets are Tomorrow's Posts
View my Flipboard Magazine.
View my Flipboard Magazine.
View my Flipboard Magazine.
View my Flipboard Magazine.

When you change the way you look at things, the things you look at change

Search This Blog

Sunday, February 1, 2009

Advances in the Treatment of Non-Hodgkin’s Lymphoma

New and Novel Agents for the Treatment of Non-Hodgkin's Lymphoma: A Report from the 2008 Meeting of the American Society of Hematology

The 2008 ASH meeting featured several reports of new agents that are showing promise in the treatment of Non-Hodgkin's Lymphoma (NHL).

Revlimid for Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Revlimid® (lenalidomide) is an orally administered derivative of thalidomide, a very active agent for the treatment of multiple myeloma. Revlimid also has anti-angiogeneic properties as well as numerous possible immune and biologic properties. Clinical trials have also documented activity for Revlimid in renal cell carcinoma, myelodysplastic syndromes, and CLL. Revlimid also has significant activity in patients with relapsed or refractory aggressive NHL, including mantle cell lymphoma. | @ltaLINK | @ltaSEARCH

No comments:

SUBSCRIBE to This Blog

Enter your email address:

Delivered by FeedBurner

Today ▶ Canswerist®

▶ SLIDESHOW   ▶ NUZZEL “NEXT” story archive for 15Feb18 ▶ Alzheimer’s Cure in sight?   ▶ Health concerns for the 5...

Privacy Notice

Privacy Notice: The sites and blogs of ALTACITIES conform to these PRIVACY PRACTICES.